Publication | Closed Access

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma

OncologyPreclinical ModelsMedicineCytostatic AgentsBronchial NeoplasmAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyLung CancerCancer ResearchHealth Sciences